Positron emission tomographic imaging of iodine 124 anti-prostate stem cell antigen-engineered antibody fragments in LAPC-9 tumor-bearing severe combined immunodeficiency mice

Molecular Imaging

Volumn 12, Issue 3, 2013, Pages 191-202

  Fonge, Humphrey ^a   Leyton, Jeffrey V ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY FRAGMENT; HIGH CONTRAST IMAGING; HUMANIZED ANTIBODY; POSITRON EMISSION; POSITRON EMISSION TOMOGRAPHY (PET); REGIONS OF INTEREST; SEVERE COMBINED IMMUNODEFICIENCIES; TOMOGRAPHIC IMAGING;

ANTIGENS; DISEASES; HISTOLOGY; MAMMALS; POSITRON EMISSION TOMOGRAPHY; RADIATION; RADIOACTIVITY; STEM CELLS; TUMORS; UROLOGY;

ANTIBODIES;

ANTIBODY; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PSCA PROTEIN, HUMAN; RADIOACTIVE IODINE; TUMOR ANTIGEN; TUMOR PROTEIN;

ANIMAL; CHEMISTRY; IMMUNOLOGY; MALE; MOUSE; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSTATIC NEOPLASMS; SCID MOUSE;

ANIMALS; ANTIBODIES; ANTIGENS, NEOPLASM; GPI-LINKED PROTEINS; IODINE RADIOISOTOPES; MALE; MICE; MICE, SCID; NEOPLASM PROTEINS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 84879216242     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2012.00033     Document Type: Article

References (41)

1. Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243:28-53, doi: 10.1148/radiol.2431030580.
2. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167:2435-9, doi:10.1016/S0022-5347(05)64999- 3.
3. Hricak H. New horizons in genitourinary oncologic imaging. Abdom Imaging 2006;31:182-7, doi:10.1007/s00261-005-0385-6.
4. O'Dowd GJ, Veltri RW, Orozco R, et al. Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol 1997;158:687-98, doi:10.1016/S0022-5347(01)64295-2.
5. Liu IJ, Zafar MB, Lai YH, et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001;57:108-11, doi:10.1016/S0090-4295(00)00896-7.
6. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002;4:99-104, doi:10.1016/S1095-0397(01)00065-6.
7. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose. Radiology 1996;199:751-6.
8. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36, doi:10.3322/caac.20121.
9. Reckwitz T, Potter SR, Partin AW. Prediction of locoregional extension and metastatic disease in prostate cancer: a review. World J Urol 2000;18:165-72, doi:10.1007/PL00007073.
10. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998;95:1735-40, doi:10.1073/pnas.95.4.1735.
11. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19: 1288-96, doi:10.1038/sj.onc.1203426.
12. Lam JS, Yamashiro J, Shintaku IP, et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005;11:2591-6, doi:10.1158/1078-0432.CCR-04-1842.
13. Raff AB, Gray A, Kast WM. Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett 2009; 277:126-32, doi:10.1016/j.canlet.2008.08.034.
14. Olafsen T, Gu Z, Sherman MA, et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007;30:396-405, doi:10.1097/CJI.0b013e318031b53b.
15. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:493-507, doi:10.2165/11531280-000000000-00000.
16. Wu AM, Yazaki PJ. Designer genes: recombinant antibody fragments for biological imaging. Q J Nucl Med 2000;44:268-83.
17. Kenanova V, Olafsen T, Crow DM, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005;65:622-31.
18. Leyton JV, Olafsen T, Lepin EJ, et al. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res 2008;14:7488-96, doi:10.1158/1078-0432.CCR-07-5093.
19. Leyton JV, Olafsen T, Sherman MA, et al. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng Des Sel 2009;22: 209-16, doi:10.1093/protein/gzn055.
20. Schneider DW, Heitner T, Alicke B, et al. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111Inantimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. J Nucl Med 2009;50:435-43, doi:10.2967/jnumed.108.055608.
21. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-9.
22. Wong JY, Chu DZ, Williams LE, et al. Pilot trial evaluating an 123Ilabeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 2004;10:5014-21, doi:10.1158/1078-0432.CCR-03-0576.
23. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigenspecific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962-9.
24. Yazaki PJ, Wu AM, Tsai SW, et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug Chem 2001;12:220-8, doi:10.1021/bc000092h.
25. Hu S, Shively L, Raubitschek A, et al. Minibody: a novel engineered anticarcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055-61.
26. Olafsen T, Tan GJ, Cheung CW, et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004;17: 315-23, doi:10.1093/protein/gzh040.
27. Challita-Eid PM, Morrison K, Etessami S, et al. Monoclonal antibodies to six transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res 2007;67:5798-805, doi:10.1158/0008-5472.CAN-06-3849.
28. Craft N, Chhor C, Tran C, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgendependent tumors through a two-step process. Cancer Res 1999; 59:5030-6.
29. Saffran DC, Raitano AB, Hubert RS, et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 2001;98:2658-63, doi:10.1073/pnas.051624698.
30. Olafsen T, Kenanova VE, Wu AM. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc 2006;1:2048-60, doi:10.1038/nprot.2006.322.
31. Defrise M, Kinahan PE, Townsend DW, et al. Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging 1997;16:145-58, doi:10.1109/42.563660.
32. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003;2:131-7, doi:10.1162/ 153535003322556877.
33. Chow PL, Stout DB, Komisopoulou E, Chatziioannou AF. A method of image registration for small animal, multi-modality imaging. Phys Med Biol 2006;51:379-90, doi:10.1088/0031-9155/51/2/013.
34. Macapinlac HA, Humm JL, Akhurst T, et al. Differential metabolism and pharmacokinetics of L-[1-(11)C]-methionine and 2-[(18)F] fluoro-2-deoxy-D- glucose (FDG) in androgen independent prostate cancer. Clin Positron Imaging 1999;2:173-81, doi:10.1016/S1095-0397(99)00015-1.
35. Picchio M, Crivellaro C, Giovacchini G, et al. PET-CT for treatment planning in prostate cancer. Q J Nucl Med Mol Imaging 2009;53:245-68.
36. Mannweiler S, Amersdorfer P, Trajanoski S, et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009;15:167-72, doi:10.1007/s12253-008- 9104-2.
37. Wong TZ, Turkington TG, Polascik TJ, Coleman RE. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol 2005;184:676-80.
38. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999;162:1322-8, doi:10.1016/S0022-5347(05)68277-8.
39. Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003;170(6 Pt 2)S84-8; discussion S88-9, doi:10.1097/01.ju.0000095151.97404.7c.
40. 124I-cG250. J Nucl Med 2011;52:535-40, doi:10.2967/jnumed. 110.083295.
41. Cai W, Olafsen T, Zhang X, et al. PET imaging of colorectal cancer in xenograftbearing mice by use of an 18F-labeled T84.66 anticarcinoembryonic antigen diabody. J Nucl Med 2007;48:304-10, doi:10.2967/jnumed.107.043216.